1-[[(3S)-3-METHYL-6-(4(4,4-TRIFLUOROBUTOXY)-3,4-DIHYDRONAPHTHALEN-2YL]METHYL]AZETIDINE-3-CARBOXYLIC ACID HAVING S1P5 RECEPTOR AGONIST ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER
Provided is a compound in which the balance of the agonist activity against the S1P5 receptor relative to the SIPi receptor has been improved in order to develop a pharmaceutical useful for the treatment of S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodeg...
Gespeichert in:
| Hauptverfasser: | , , , , , |
|---|---|
| Format: | Patent |
| Sprache: | eng ; fre ; ger |
| Schlagworte: | |
| Online-Zugang: | Volltext bestellen |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | |
|---|---|
| container_issue | |
| container_start_page | |
| container_title | |
| container_volume | |
| creator | KUSUMI, Kensuke TSUBURAYA, Naomi IMAIDE, Satomi ENDO, Toshimitsu KOMIYA, Takaki WATANABE, Toshihide |
| description | Provided is a compound in which the balance of the agonist activity against the S1P5 receptor relative to the SIPi receptor has been improved in order to develop a pharmaceutical useful for the treatment of S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases. This compound represented by general formula (V) (in the formula, all symbols are as defined in the specification) has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic for SIPs-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases. |
| format | Patent |
| fullrecord | <record><control><sourceid>epo_EVB</sourceid><recordid>TN_cdi_epo_espacenet_EP3757091B1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>EP3757091B1</sourcerecordid><originalsourceid>FETCH-epo_espacenet_EP3757091B13</originalsourceid><addsrcrecordid>eNqNjMFKw0AQhnPxIOo7zDGCC8akFo-T3Ul2IN0Ns5NiLKUUiSfRQn1Kn8oFfQBPP3x8339ZfFdmtyvrdGtqsyH182AeTdmUzV1jVLgbpiixnTQ-z1nJ0LGfncSAo1ePAwXzMA_733SPL6TsOFB-syhtrga2gJYdeNxy6CFV4wqELI0aBbCPgZNmQ3nLOkOXoXoCFULdUFCIHQSaJDrqKZBgFgkcpyiOJAEGBxaDJbkuLt6O7-fl5m-vCuhIrTfL6fOwnE_H1-Vj-TrQWK9X6_unqq3qfyg_ewlPmw</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>patent</recordtype></control><display><type>patent</type><title>1-[[(3S)-3-METHYL-6-(4(4,4-TRIFLUOROBUTOXY)-3,4-DIHYDRONAPHTHALEN-2YL]METHYL]AZETIDINE-3-CARBOXYLIC ACID HAVING S1P5 RECEPTOR AGONIST ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER</title><source>esp@cenet</source><creator>KUSUMI, Kensuke ; TSUBURAYA, Naomi ; IMAIDE, Satomi ; ENDO, Toshimitsu ; KOMIYA, Takaki ; WATANABE, Toshihide</creator><creatorcontrib>KUSUMI, Kensuke ; TSUBURAYA, Naomi ; IMAIDE, Satomi ; ENDO, Toshimitsu ; KOMIYA, Takaki ; WATANABE, Toshihide</creatorcontrib><description>Provided is a compound in which the balance of the agonist activity against the S1P5 receptor relative to the SIPi receptor has been improved in order to develop a pharmaceutical useful for the treatment of S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases. This compound represented by general formula (V) (in the formula, all symbols are as defined in the specification) has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic for SIPs-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.</description><language>eng ; fre ; ger</language><subject>CHEMISTRY ; HETEROCYCLIC COMPOUNDS ; HUMAN NECESSITIES ; HYGIENE ; MEDICAL OR VETERINARY SCIENCE ; METALLURGY ; ORGANIC CHEMISTRY ; PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES ; SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><creationdate>2024</creationdate><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240828&DB=EPODOC&CC=EP&NR=3757091B1$$EHTML$$P50$$Gepo$$Hfree_for_read</linktohtml><link.rule.ids>230,308,780,885,25564,76547</link.rule.ids><linktorsrc>$$Uhttps://worldwide.espacenet.com/publicationDetails/biblio?FT=D&date=20240828&DB=EPODOC&CC=EP&NR=3757091B1$$EView_record_in_European_Patent_Office$$FView_record_in_$$GEuropean_Patent_Office$$Hfree_for_read</linktorsrc></links><search><creatorcontrib>KUSUMI, Kensuke</creatorcontrib><creatorcontrib>TSUBURAYA, Naomi</creatorcontrib><creatorcontrib>IMAIDE, Satomi</creatorcontrib><creatorcontrib>ENDO, Toshimitsu</creatorcontrib><creatorcontrib>KOMIYA, Takaki</creatorcontrib><creatorcontrib>WATANABE, Toshihide</creatorcontrib><title>1-[[(3S)-3-METHYL-6-(4(4,4-TRIFLUOROBUTOXY)-3,4-DIHYDRONAPHTHALEN-2YL]METHYL]AZETIDINE-3-CARBOXYLIC ACID HAVING S1P5 RECEPTOR AGONIST ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER</title><description>Provided is a compound in which the balance of the agonist activity against the S1P5 receptor relative to the SIPi receptor has been improved in order to develop a pharmaceutical useful for the treatment of S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases. This compound represented by general formula (V) (in the formula, all symbols are as defined in the specification) has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic for SIPs-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.</description><subject>CHEMISTRY</subject><subject>HETEROCYCLIC COMPOUNDS</subject><subject>HUMAN NECESSITIES</subject><subject>HYGIENE</subject><subject>MEDICAL OR VETERINARY SCIENCE</subject><subject>METALLURGY</subject><subject>ORGANIC CHEMISTRY</subject><subject>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</subject><subject>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</subject><fulltext>true</fulltext><rsrctype>patent</rsrctype><creationdate>2024</creationdate><recordtype>patent</recordtype><sourceid>EVB</sourceid><recordid>eNqNjMFKw0AQhnPxIOo7zDGCC8akFo-T3Ul2IN0Ns5NiLKUUiSfRQn1Kn8oFfQBPP3x8339ZfFdmtyvrdGtqsyH182AeTdmUzV1jVLgbpiixnTQ-z1nJ0LGfncSAo1ePAwXzMA_733SPL6TsOFB-syhtrga2gJYdeNxy6CFV4wqELI0aBbCPgZNmQ3nLOkOXoXoCFULdUFCIHQSaJDrqKZBgFgkcpyiOJAEGBxaDJbkuLt6O7-fl5m-vCuhIrTfL6fOwnE_H1-Vj-TrQWK9X6_unqq3qfyg_ewlPmw</recordid><startdate>20240828</startdate><enddate>20240828</enddate><creator>KUSUMI, Kensuke</creator><creator>TSUBURAYA, Naomi</creator><creator>IMAIDE, Satomi</creator><creator>ENDO, Toshimitsu</creator><creator>KOMIYA, Takaki</creator><creator>WATANABE, Toshihide</creator><scope>EVB</scope></search><sort><creationdate>20240828</creationdate><title>1-[[(3S)-3-METHYL-6-(4(4,4-TRIFLUOROBUTOXY)-3,4-DIHYDRONAPHTHALEN-2YL]METHYL]AZETIDINE-3-CARBOXYLIC ACID HAVING S1P5 RECEPTOR AGONIST ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER</title><author>KUSUMI, Kensuke ; TSUBURAYA, Naomi ; IMAIDE, Satomi ; ENDO, Toshimitsu ; KOMIYA, Takaki ; WATANABE, Toshihide</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-epo_espacenet_EP3757091B13</frbrgroupid><rsrctype>patents</rsrctype><prefilter>patents</prefilter><language>eng ; fre ; ger</language><creationdate>2024</creationdate><topic>CHEMISTRY</topic><topic>HETEROCYCLIC COMPOUNDS</topic><topic>HUMAN NECESSITIES</topic><topic>HYGIENE</topic><topic>MEDICAL OR VETERINARY SCIENCE</topic><topic>METALLURGY</topic><topic>ORGANIC CHEMISTRY</topic><topic>PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES</topic><topic>SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS</topic><toplevel>online_resources</toplevel><creatorcontrib>KUSUMI, Kensuke</creatorcontrib><creatorcontrib>TSUBURAYA, Naomi</creatorcontrib><creatorcontrib>IMAIDE, Satomi</creatorcontrib><creatorcontrib>ENDO, Toshimitsu</creatorcontrib><creatorcontrib>KOMIYA, Takaki</creatorcontrib><creatorcontrib>WATANABE, Toshihide</creatorcontrib><collection>esp@cenet</collection></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext_linktorsrc</fulltext></delivery><addata><au>KUSUMI, Kensuke</au><au>TSUBURAYA, Naomi</au><au>IMAIDE, Satomi</au><au>ENDO, Toshimitsu</au><au>KOMIYA, Takaki</au><au>WATANABE, Toshihide</au><format>patent</format><genre>patent</genre><ristype>GEN</ristype><title>1-[[(3S)-3-METHYL-6-(4(4,4-TRIFLUOROBUTOXY)-3,4-DIHYDRONAPHTHALEN-2YL]METHYL]AZETIDINE-3-CARBOXYLIC ACID HAVING S1P5 RECEPTOR AGONIST ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER</title><date>2024-08-28</date><risdate>2024</risdate><abstract>Provided is a compound in which the balance of the agonist activity against the S1P5 receptor relative to the SIPi receptor has been improved in order to develop a pharmaceutical useful for the treatment of S1P5-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases. This compound represented by general formula (V) (in the formula, all symbols are as defined in the specification) has an improved balance of the agonist activity against the S1P5 receptor relative to the S1P1 receptor, and can thus serve as a therapeutic for SIPs-mediated diseases such as schizophrenia and Binswanger's disease and other neurodegenerative diseases.</abstract><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext_linktorsrc |
| identifier | |
| ispartof | |
| issn | |
| language | eng ; fre ; ger |
| recordid | cdi_epo_espacenet_EP3757091B1 |
| source | esp@cenet |
| subjects | CHEMISTRY HETEROCYCLIC COMPOUNDS HUMAN NECESSITIES HYGIENE MEDICAL OR VETERINARY SCIENCE METALLURGY ORGANIC CHEMISTRY PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS |
| title | 1-[[(3S)-3-METHYL-6-(4(4,4-TRIFLUOROBUTOXY)-3,4-DIHYDRONAPHTHALEN-2YL]METHYL]AZETIDINE-3-CARBOXYLIC ACID HAVING S1P5 RECEPTOR AGONIST ACTIVITY FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS AND CANCER |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-28T21%3A40%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-epo_EVB&rft_val_fmt=info:ofi/fmt:kev:mtx:patent&rft.genre=patent&rft.au=KUSUMI,%20Kensuke&rft.date=2024-08-28&rft_id=info:doi/&rft_dat=%3Cepo_EVB%3EEP3757091B1%3C/epo_EVB%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_id=info:pmid/&rfr_iscdi=true |